Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Debt to Equity (2018 - 2023)

X4 Pharmaceuticals (XFOR) has disclosed Debt to Equity for 5 consecutive years, with $0.01 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Debt to Equity fell 96.05% year-over-year to $0.01, compared with a TTM value of $0.01 through Jun 2023, down 96.05%, and an annual FY2022 reading of $0.02, up 43.88% over the prior year.
  • Debt to Equity was $0.01 for Q2 2023 at X4 Pharmaceuticals, up from $0.01 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.29 in Q2 2022 and bottomed at $0.01 in Q3 2021.
  • Average Debt to Equity over 4 years is $0.11, with a median of $0.04 recorded in 2022.
  • The sharpest move saw Debt to Equity surged 2242.8% in 2022, then crashed 96.05% in 2023.
  • Year by year, Debt to Equity stood at $0.27 in 2019, then plummeted by 95.5% to $0.01 in 2021, then surged by 43.88% to $0.02 in 2022, then plummeted by 36.3% to $0.01 in 2023.
  • Business Quant data shows Debt to Equity for XFOR at $0.01 in Q2 2023, $0.01 in Q1 2023, and $0.02 in Q4 2022.